CNBX Pharmaceuticals Inc. (CNBX)
USD 0.01
(5.93%)
USD 0.01
(5.93%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.51 Million USD | 2.98% |
| 2022 | 2.44 Million USD | 91.94% |
| 2021 | 1.27 Million USD | 179.92% |
| 2020 | 454.78 Thousand USD | 3.63% |
| 2019 | 438.87 Thousand USD | -18.63% |
| 2018 | 539.38 Thousand USD | -22.85% |
| 2017 | 699.12 Thousand USD | 42.34% |
| 2016 | 491.16 Thousand USD | 45.17% |
| 2015 | 338.33 Thousand USD | 356.34% |
| 2014 | 74.14 Thousand USD | -58.38% |
| 2013 | 178.14 Thousand USD | 263.63% |
| 2012 | 48.99 Thousand USD | 3.49% |
| 2011 | 47.34 Thousand USD | 35.3% |
| 2010 | 34.99 Thousand USD | -90.08% |
| 2009 | 352.69 Thousand USD | 20756.95% |
| 2008 | 1691.00 USD | 0.0% |
| 2007 | - USD | -100.0% |
| 2006 | 27.09 Thousand USD | -3.37% |
| 2005 | 28.03 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 2.53 Million USD | 0.47% |
| 2024 Q1 | 2.48 Million USD | -1.35% |
| 2024 Q2 | 2.52 Million USD | 1.62% |
| 2023 Q3 | 2.57 Million USD | 3.96% |
| 2023 Q1 | 2.58 Million USD | 5.74% |
| 2023 Q4 | 2.51 Million USD | -2.14% |
| 2023 FY | 2.51 Million USD | 2.98% |
| 2023 Q2 | 2.47 Million USD | -4.27% |
| 2022 Q1 | 1.49 Million USD | 17.26% |
| 2022 FY | 2.44 Million USD | 91.94% |
| 2022 Q2 | 1.78 Million USD | 19.63% |
| 2022 Q3 | 2.14 Million USD | 20.29% |
| 2022 Q4 | 2.44 Million USD | 13.74% |
| 2021 Q4 | 1.27 Million USD | -13.4% |
| 2021 Q2 | 1.18 Million USD | 167.46% |
| 2021 Q1 | 442.68 Thousand USD | -2.66% |
| 2021 FY | 1.27 Million USD | 179.92% |
| 2021 Q3 | 1.47 Million USD | 24.15% |
| 2020 Q2 | 419.64 Thousand USD | -4.73% |
| 2020 Q1 | 440.45 Thousand USD | 0.36% |
| 2020 Q3 | 430.13 Thousand USD | 2.5% |
| 2020 Q4 | 454.78 Thousand USD | 5.73% |
| 2020 FY | 454.78 Thousand USD | 3.63% |
| 2019 Q4 | 438.87 Thousand USD | -3.36% |
| 2019 Q1 | 412.74 Thousand USD | -23.48% |
| 2019 Q2 | 376.18 Thousand USD | -8.86% |
| 2019 FY | 438.87 Thousand USD | -18.63% |
| 2019 Q3 | 454.13 Thousand USD | 20.72% |
| 2018 Q2 | 474.75 Thousand USD | -25.79% |
| 2018 Q4 | 539.38 Thousand USD | 3.06% |
| 2018 FY | 539.38 Thousand USD | -22.85% |
| 2018 Q1 | 639.75 Thousand USD | -8.49% |
| 2018 Q3 | 523.34 Thousand USD | 10.23% |
| 2017 Q4 | 699.12 Thousand USD | 19.26% |
| 2017 Q3 | 586.21 Thousand USD | -23.82% |
| 2017 Q2 | 769.5 Thousand USD | 49.87% |
| 2017 Q1 | 513.44 Thousand USD | 4.54% |
| 2017 FY | 699.12 Thousand USD | 42.34% |
| 2016 Q3 | 491.43 Thousand USD | 1.85% |
| 2016 FY | 491.16 Thousand USD | 45.17% |
| 2016 Q4 | 491.16 Thousand USD | -0.05% |
| 2016 Q1 | 120.5 Thousand USD | -64.38% |
| 2016 Q2 | 482.51 Thousand USD | 300.41% |
| 2015 Q3 | 203.3 Thousand USD | 203.39% |
| 2015 FY | 338.33 Thousand USD | 356.34% |
| 2015 Q1 | 78.52 Thousand USD | 5.91% |
| 2015 Q2 | 67.01 Thousand USD | -14.66% |
| 2015 Q4 | 338.33 Thousand USD | 66.41% |
| 2014 Q3 | 3798.00 USD | -92.55% |
| 2014 FY | 74.14 Thousand USD | -58.38% |
| 2014 Q4 | 74.14 Thousand USD | 1852.08% |
| 2014 Q1 | 50.08 Thousand USD | -71.88% |
| 2014 Q2 | 51 Thousand USD | 1.82% |
| 2013 Q2 | 68.76 Thousand USD | 7.23% |
| 2013 Q1 | 64.12 Thousand USD | 30.9% |
| 2013 FY | 178.14 Thousand USD | 263.63% |
| 2013 Q4 | 178.14 Thousand USD | 142.4% |
| 2013 Q3 | 73.49 Thousand USD | 6.87% |
| 2012 Q1 | 57.58 Thousand USD | 21.64% |
| 2012 Q3 | 63.43 Thousand USD | 6.73% |
| 2012 Q4 | 48.99 Thousand USD | -22.77% |
| 2012 FY | 48.99 Thousand USD | 3.49% |
| 2012 Q2 | 59.43 Thousand USD | 3.21% |
| 2011 Q4 | 47.34 Thousand USD | -92.43% |
| 2011 Q1 | 43.79 Thousand USD | 25.17% |
| 2011 Q3 | 625.68 Thousand USD | 1201.21% |
| 2011 Q2 | 48.08 Thousand USD | 9.79% |
| 2011 FY | 47.34 Thousand USD | 35.3% |
| 2010 FY | 34.99 Thousand USD | -90.08% |
| 2010 Q4 | 34.99 Thousand USD | 4.05% |
| 2010 Q3 | 33.62 Thousand USD | 6.87% |
| 2010 Q2 | 31.46 Thousand USD | 429.23% |
| 2010 Q1 | 5946.00 USD | -98.31% |
| 2009 Q1 | 5971.00 USD | 253.1% |
| 2009 FY | 352.69 Thousand USD | 20756.95% |
| 2009 Q4 | 352.69 Thousand USD | 21806.27% |
| 2009 Q3 | 1610.00 USD | -20.92% |
| 2009 Q2 | 2036.00 USD | -65.9% |
| 2008 Q4 | 1691.00 USD | 369.72% |
| 2008 Q3 | 360.00 USD | 188.0% |
| 2008 Q2 | 125.00 USD | -98.02% |
| 2008 Q1 | 6305.00 USD | 0.0% |
| 2008 FY | 1691.00 USD | 0.0% |
| 2007 Q1 | 25.27 Thousand USD | -6.72% |
| 2007 Q2 | 27.06 Thousand USD | 7.08% |
| 2007 FY | - USD | -100.0% |
| 2007 Q3 | 25.14 Thousand USD | -7.08% |
| 2007 Q4 | - USD | -100.0% |
| 2006 Q1 | 32.54 Thousand USD | 0.0% |
| 2006 Q4 | 27.09 Thousand USD | -18.11% |
| 2006 Q3 | 33.08 Thousand USD | 7.1% |
| 2006 Q2 | 30.88 Thousand USD | -5.09% |
| 2006 FY | 27.09 Thousand USD | -3.37% |
| 2005 FY | 28.03 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -9072.632% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 73.417% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 96.528% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -211.121% |
| Rebus Holdings, Inc. | 5.24 Million USD | 51.997% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 95.736% |
| Qrons Inc. | 1.48 Million USD | -69.027% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -105.211% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 96.641% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -5529.873% |
| Skye Bioscience, Inc. | 14.07 Million USD | 82.118% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 95.279% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 73.739% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -496.897% |
| SQZ Biotechnologies Company | 50.03 Million USD | 94.971% |
| Intellipharmaceutics International Inc. | 12 Million USD | 79.046% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 34.665% |
| Mesoblast Limited | 188.44 Million USD | 98.665% |
| Marizyme, Inc. | 26.67 Million USD | 90.567% |
| Genus plc | 485 Million USD | 99.481% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 56.932% |
| Pharming Group N.V. | 244.07 Million USD | 98.969% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -25.182% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 33.781% |
| ContraFect Corporation | 32.53 Million USD | 92.265% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -27.003% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 34.259% |
| IMV Inc. | 37.93 Million USD | 93.366% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 78.636% |
| MultiCell Technologies, Inc. | 1617.67 USD | -155452.616% |
| ONE Bio Corp. | 27.49 Million USD | 90.848% |
| Accustem Sciences Inc. | 1.07 Million USD | -133.158% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 96.75% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -18.971% |
| Q BioMed Inc. | 8.13 Million USD | 69.06% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 96.966% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 51.102% |
| Biomind Labs Inc. | 1.49 Million USD | -67.911% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 97.88% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 72.171% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 86.327% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -75.493% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -1670.877% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -1151.182% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 56.206% |
| GB Sciences, Inc. | 5.41 Million USD | 53.552% |
| Alpha Cognition Inc. | 7.16 Million USD | 64.879% |
| HST Global, Inc. | 593.59 Thousand USD | -323.915% |
| CSL Limited | 18.62 Billion USD | 99.986% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -99.837% |
| Halberd Corporation | 728.71 Thousand USD | -245.308% |
| Enzolytics Inc. | 365.26 Million USD | 99.311% |
| Agentix Corp. | 2.51 Million USD | -0.23% |
| Resverlogix Corp. | 67.39 Million USD | 96.266% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -200.016% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.434% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -46.81% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 89.831% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 78.86% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 31.345% |
| AVAX Technologies, Inc. | 3.99 Million USD | 36.993% |
| Zenith Capital Corp. | 27.56 Thousand USD | -9027.382% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.81% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -954.383% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 32.616% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -269.595% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 7.203% |
| Kadimastem Ltd | 3.5 Million USD | 28.205% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -3659.698% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 94.994% |
| BioStem Technologies, Inc. | 15.9 Million USD | 84.179% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -441.496% |
| LadRx Corporation | 2.2 Million USD | -14.351% |
| Cell Source, Inc. | 15.8 Million USD | 84.081% |
| Regen BioPharma, Inc. | 5.45 Million USD | 53.893% |
| Regen BioPharma, Inc. | 5.45 Million USD | 53.893% |
| NovAccess Global Inc. | 7.86 Million USD | 67.989% |
| Affymax, Inc. | 8.87 Million USD | 71.634% |
| Itoco Inc. | 1.65 Million USD | -52.214% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -22.654% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 58.401% |
| Mobile Lads Corp. | 1.31 Million USD | -91.575% |
| CytoDyn Inc. | 127.89 Million USD | 98.032% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -5920.067% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -60.646% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 77.218% |
| SYBLEU INC | 681.41 Thousand USD | -269.281% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 58.762% |
| International Stem Cell Corporation | 5.27 Million USD | 52.315% |
| Bioxytran, Inc. | 3.24 Million USD | 22.563% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -302.092% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 45.5% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 93.862% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 88.698% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -24.239% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 54.065% |
| Neutra Corp. | 973.52 Thousand USD | -158.475% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 91.327% |
| PureTech Health plc | 125.58 Million USD | 97.996% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 33.025% |
| IXICO plc | 1.9 Million USD | -32.418% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 87.743% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 97.565% |
| CSL Limited | 18.62 Billion USD | 99.986% |
| Cellectis S.A. | 249.36 Million USD | 98.991% |